OncoMatch/Clinical Trials/NCT06939855
QL1706 in the Treatment of Advanced Bone and Soft Tissue Sarcoma
Is NCT06939855 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies QL1706 (bispecific antibody targeting PD-1 and CLTA-4) for bone and soft tissue tumors.
Treatment: QL1706 (bispecific antibody targeting PD-1 and CLTA-4) — This is a single-center, open-label phase II study of QL1706 for the treatment of advanced bone and soft tissue sarcomas.The study includes screening period, treatment period and follow-up period. Subjects will receive QL1706 5mg/kg iv every 3 weeks until disease progression or intolerance. Efficacy should be evaluated and safety will be monitored throughout the study.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Biomarker criteria
Required: PD-L1 (CD274) any tested (testing required; no eligibility threshold specified)
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Must have received: anthracycline — for undifferentiated sarcoma, leiomyosarcoma, myxofibrosarcoma, dedifferentiated liposarcoma, pleomorphic undifferentiated sarcoma
subjects must have received anthracycline-based chemotherapy
Must have received: paclitaxel (paclitaxel) — for angiosarcoma
Subjects with angiosarcoma must have received paclitaxel- or anthracycline-based chemotherapy, and have developed metastasis or disease progression (≥10% increase in the sum of the longest diameters within 3 months), or be intolerant to standard therapy.
Must have received: anthracycline — for angiosarcoma
Subjects with angiosarcoma must have received paclitaxel- or anthracycline-based chemotherapy, and have developed metastasis or disease progression (≥10% increase in the sum of the longest diameters within 3 months), or be intolerant to standard therapy.
Cannot have received: anti-PD-1 therapy
Exception: Subjects treated more than 5 years earlier and with no clinical evidence of disease recurrence within the past 5 years may be eligible.
Prior treatment with immune checkpoint inhibitors (PD-1/PD-L1 agents) or other agents targeting T-cell receptor signaling (for example CTLA-4, OX-40).
Cannot have received: anti-PD-L1 therapy
Exception: Subjects treated more than 5 years earlier and with no clinical evidence of disease recurrence within the past 5 years may be eligible.
Prior treatment with immune checkpoint inhibitors (PD-1/PD-L1 agents) or other agents targeting T-cell receptor signaling (for example CTLA-4, OX-40).
Cannot have received: anti-CTLA-4 therapy
Exception: Subjects treated more than 5 years earlier and with no clinical evidence of disease recurrence within the past 5 years may be eligible.
Prior treatment with immune checkpoint inhibitors (PD-1/PD-L1 agents) or other agents targeting T-cell receptor signaling (for example CTLA-4, OX-40).
Cannot have received: OX-40 inhibitor
Exception: Subjects treated more than 5 years earlier and with no clinical evidence of disease recurrence within the past 5 years may be eligible.
Prior treatment with immune checkpoint inhibitors (PD-1/PD-L1 agents) or other agents targeting T-cell receptor signaling (for example CTLA-4, OX-40).
Lab requirements
Blood counts
ANC ≥1.5 × 10⁹/L; Platelet count ≥90 × 10⁹/L; Hemoglobin ≥90 g/L.
Kidney function
Serum creatinine ≤1.5 × ULN or creatinine clearance ≥50 mL/min (Cockcroft-Gault).
Liver function
AST and ALT ≤2.5 × ULN; for subjects with liver metastasis, AST and ALT ≤5 × ULN. Total bilirubin ≤1.5 × ULN (subjects with Gilbert syndrome: TBIL <3 × ULN). Albumin ≥30 g/L.
Cardiac function
Left ventricular ejection fraction (LVEF) ≥50%.
Clinical laboratory tests at screening must meet the following criteria: Hematologic: ANC ≥1.5 × 10⁹/L; Platelet count ≥90 × 10⁹/L; Hemoglobin ≥90 g/L. Hepatic: AST and ALT ≤2.5 × ULN; for subjects with liver metastasis, AST and ALT ≤5 × ULN. Total bilirubin ≤1.5 × ULN (subjects with Gilbert syndrome: TBIL <3 × ULN). Albumin ≥30 g/L. Renal: Serum creatinine ≤1.5 × ULN or creatinine clearance ≥50 mL/min (Cockcroft-Gault). Cardiac: LVEF ≥50%.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06939855 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior anti-PD-1 therapy, anti-PD-L1 therapy, anti-CTLA-4 therapy disqualifies patients from enrollment.
Does this trial require CD274?
Yes, CD274 any tested is a required biomarker for enrollment.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify